Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4163974 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53L3MBTL1ACLY | |
| Trifluoroacetic Acid SCHEMBL4809831 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53L3MBTL1ACLY | |
| Trifluoroacetic Acid SCHEMBL1525100 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53L3MBTL1ACLY | |
| Trifluoroacetic Acid SCHEMBL3634014 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53L3MBTL1ACLY | |
| Trifluoroacetic Acid SCHEMBL19552101 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53L3MBTL1ACLY | |
| Trifluoroacetic Acid SCHEMBL9632138 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53L3MBTL1ACLY | |
| Trifluoroacetic Acid SCHEMBL19552090 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53L3MBTL1ACLY | |
| Trifluoroacetic Acid SCHEMBL60574 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53L3MBTL1ACLY | |
| Trifluoroacetic Acid SCHEMBL6864080 | 0.94 | TSHR (0.35) | ALDH1A1TSHRTP53L3MBTL1ACLY | |
| Trifluoroacetic Acid SCHEMBL11086962 | 0.93 | ALDH1A1 (0.39) | ALDH1A1TSHRTP53L3MBTL1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112341355-B | Chlorogenic acid derivative and preparation method and application thereof | 中国医学科学院药用植物研究所 | 2022-08-30 | — | — | CN | disclosed |
| CN-112341355-A | Chlorogenic acid derivative and preparation method and application thereof | 中国医学科学院药用植物研究所 | 2021-02-09 | — | — | CN | disclosed |
| US-20170275334-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9708368-B2 | Linear peptide antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150166605-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8999922-B2 | Linear peptide antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130217619-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2111396-B1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | JANSSEN R & D IRELAND (IE) | 2013-08-07 | — | — | EP | disclosed |
| US-8383584-B2 | HCV inhibiting macrocyclic phenylcarbamates | MEDIVIR AB (SE) | 2013-02-26 | — | — | US | disclosed |
| EP-1919898-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-26 | — | — | EP | disclosed |
| US-6399656-B1 | USING A BENZOPYRAN-3-CARBOXAMIDE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-06-04 | — | — | US | disclosed |
| WO-2002026774-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| EP-1102535-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1100495-A1 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1001766-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000006146-A9 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1001766-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000006153-A1 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006085-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999001127-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166605-A1 | LINEAR PEPTIDE ANTIBIOTICS | SPAST, PEPD, NPEPPS | THRB 3228/4885MEN1 3672/4885ALDH1A1 3907/4885 |
| US-20170275334-A1 | LINEAR PEPTIDE ANTIBIOTICS | SPAST, PEPD, NPEPPS | THRB 3228/4885MEN1 3672/4885ALDH1A1 3907/4885 |
| US-20130217619-A1 | LINEAR PEPTIDE ANTIBIOTICS | SPAST, PEPD, NPEPPS | THRB 3228/4885MEN1 3672/4885ALDH1A1 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.